GlassScriptPhysician profile
Michael Todd Peacock
NPI 1487636742
$7,256.69
in general payments reported to CMS, 2019-2025
43 companies · $1,935 in 2025
The $1,935 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,077 · 2020: $694 · 2021: $560 · 2022: $984 · 2023: $846 · 2024: $1,160 · 2025: $1,935.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,860 · Education: $81.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,860.30 |
| Education | $81.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $813.14 | 2023-2025 | Rexulti, Nuedexta |
| Neurocrine Biosciences, INC. | $810.54 | 2022-2025 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $632.97 | 2019-2022 | |
| Ucb, INC. | $445.08 | 2021-2025 | Briviact, Nayzilam |
| Astrazeneca Pharmaceuticals LP | $438.46 | 2019-2025 | Lokelma, Airsupra, Breztri |
| Sk Life Science, INC. | $314.88 | 2024-2025 | |
| Urovant Sciences INC | $293.21 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $291.73 | 2023-2025 | Aptiom, Gemtesa |
| Janssen Pharmaceuticals, INC | $280.85 | 2019-2020 | |
| Alkermes, INC. | $242.95 | 2023-2024 | Aristada, Lybalvi, Aristada Initio |
| Novo Nordisk INC | $211.95 | 2019-2025 | Wegovy |
| Acadia Pharmaceuticals INC | $196.07 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $185.80 | 2019-2025 | Jardiance |
| Esperion Therapeutics, INC. | $154.50 | 2021-2025 | Nexletol |
| Lundbeck LLC | $153.82 | 2024-2025 | Rexulti |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Peacock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.